Adding and deleting users on your Xbox Series X is simple and each other requires a few quick selections to make either happen. Signed in or not, a fast way to add an account to your Xbox starts with ...

While most enterprises lock down endpoints, harden networks, and scan for vulnerabilities, one of the riskiest vectors often slips through unmonitored: browser extensions. These small, user-installed ...

Free agent guard Malcolm Brogdon has agreed to a one-year deal with the New York Knicks, agent Sam Permut of Roc Nation told ESPN on Friday morning. Entering his 10th NBA season, Brogdon, a former ...

The internet is changing rapidly. The blue links we saw on the search are going away, and people are increasingly finding the answers spelled out like a textbook using AI chatbots. As a result, we are ...

ALBANY, N.Y.--(BUSINESS WIRE)--Soluna Holdings, Inc. (“Soluna” or the “Company”), (NASDAQ: SLNH), a developer of green data centers for intensive computing applications, including AI and Bitcoin ...

Data center capacity has become a barometer for both the health of the tech market and the risk of an A.I. bubble. By Ian Frisch Trillions of dollars are flowing into the data centers needed to power ...

Google is adding multiple new AI features to Chrome, the most popular browser in the world. The most visible change is a new button in Chrome that launches the Gemini chatbot, but there are also new ...

As you’ve probably heard, if not also experienced, AI is reshaping how we work. If you happen to be a senior professional with sufficient reputational capital, status, and a deep social network, you ...

In a quest to bolster a long-running claim from President Trump concerning undocumented immigrants illegally voting, the Justice Department is seeking detailed voter roll data from over 30 states. By ...

A debate is raging among Wikipedia editors over whether to delete the profile page of Erika Kirk, wife of slain conservative activist Charlie Kirk. Her Wikipedia entry is currently locked, with users ...

The MARIPOSA trial demonstrates that amivantamab plus lazertinib significantly reduces resistance and extends survival in EGFR-mutated NSCLC compared to osimertinib. Dual inhibition of EGFR and MET by ...